loading
Schlusskurs vom Vortag:
$7.38
Offen:
$7.45
24-Stunden-Volumen:
420.03K
Relative Volume:
1.76
Marktkapitalisierung:
$507.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+13.55%
1M Leistung:
+9.53%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$7.38
$7.78
1-Wochen-Bereich:
Value
$6.6099
$7.78
52-Wochen-Spanne:
Value
$5.33
$7.9999

Niagen Bioscience Inc Stock (NAGE) Company Profile

Name
Firmenname
Niagen Bioscience Inc
Name
Telefon
310-388-6706
Name
Adresse
10900 WILSHIRE BLVD, LOS ANGELES
Name
Mitarbeiter
104
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
NAGE's Discussions on Twitter

Vergleichen Sie NAGE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NAGE
Niagen Bioscience Inc
7.44 507.71M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.76 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
606.78 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
615.52 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.21 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
250.19 24.70B 3.81B -644.79M -669.77M -6.24

Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-08-16 Herabstufung Oppenheimer Outperform → Perform
2022-08-11 Herabstufung B. Riley Securities Buy → Neutral
2022-03-08 Eingeleitet ROTH Capital Buy
2019-10-16 Eingeleitet Oppenheimer Outperform
2019-02-14 Eingeleitet B. Riley FBR Buy
2017-11-27 Fortgesetzt H.C. Wainwright Buy
2017-09-25 Eingeleitet Ladenburg Thalmann Buy
2017-01-03 Eingeleitet Rodman & Renshaw Buy
Alle ansehen

Niagen Bioscience Inc Aktie (NAGE) Neueste Nachrichten

pulisher
08:34 AM

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - Bluefield Daily Telegraph

08:34 AM
pulisher
07:17 AM

Is Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st

07:17 AM
pulisher
Apr 24, 2025

Niagen Bioscience Inc [NAGE] stock for 2,146 USD was acquired by Lopez Carlos Luis - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Is it possible to buy Niagen Bioscience Inc(NAGE) shares at a good price now? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Niagen Bioscience, Inc.'s (NASDAQ:NAGE) market cap up US$51m last week, benefiting both individual investors who own 36% as well as insiders - Yahoo Finance

Apr 24, 2025
pulisher
Apr 21, 2025

Supplement Maker Rebrands - Los Angeles Business Journal

Apr 21, 2025
pulisher
Apr 10, 2025

Robert Fried Exercises Options, Realizes $173KNiagen Bioscience (NASDAQ:NAGE) - Benzinga

Apr 10, 2025
pulisher
Apr 09, 2025

Market Resilience: Niagen Bioscience Inc (NAGE) Finishes Weak at 5.42, Down -3.56 - DWinneX

Apr 09, 2025
pulisher
Apr 07, 2025

Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs - marketscreener.com

Apr 07, 2025
pulisher
Apr 07, 2025

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - Business Wire

Apr 07, 2025
pulisher
Apr 07, 2025

Niagen Bioscience maintains stability amid tariffs By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Niagen Bioscience Stands Firm Despite Global Tariff Concerns - Finimize

Apr 07, 2025
pulisher
Apr 07, 2025

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Niagen Bioscience maintains stability amid tariffs - Investing.com

Apr 07, 2025
pulisher
Apr 05, 2025

Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues - simplywall.st

Apr 05, 2025
pulisher
Apr 03, 2025

Growth Companies With High Insider Ownership For April 2025 - Yahoo Finance

Apr 03, 2025
pulisher
Apr 02, 2025

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - MarketScreener

Apr 02, 2025
pulisher
Mar 31, 2025

H.C. Wainwright holds $11 target on Niagen Bioscience stock By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

H.C. Wainwright holds $11 target on Niagen Bioscience stock - Investing.com

Mar 31, 2025
pulisher
Mar 29, 2025

A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE) - simplywall.st

Mar 29, 2025
pulisher
Mar 21, 2025

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - MarketScreener

Mar 21, 2025
pulisher
Mar 21, 2025

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results - MarketScreener

Mar 21, 2025
pulisher
Mar 20, 2025

Niagen Bioscience broadens NAD+ precursor IP portfolio with new patent - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Niagen Bioscience secures new patent for NAD+ precursors - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire

Mar 20, 2025
pulisher
Mar 19, 2025

Niagen Bioscience, Inc. Rings the Closing Bell - Nasdaq

Mar 19, 2025
pulisher
Mar 19, 2025

ChromaDex Completes Name Change to Niagen Bioscience -March 19, 2025 at 09:29 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Chromadex Rebrands to Niagen Bioscience, Inc. - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - The Bakersfield Californian

Mar 19, 2025
pulisher
Mar 19, 2025

ChromaDex Corporation will Change its Ticker to NAGE from CDXC - marketscreener.com

Mar 19, 2025
pulisher
Mar 17, 2025

ChromaDex changes name to Niagen Bioscience to home in on healthy aging - SupplySide Supplement Journal

Mar 17, 2025
pulisher
Mar 17, 2025

Chromadex’s Strategic Rebranding and Promising Clinical Developments Justify Buy Rating - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

ChromaDex rebrands as Niagen Bioscience to reflect growth in supplement, pharmaceutical industries - NutraIngredients-USA.com

Mar 17, 2025
pulisher
Mar 14, 2025

ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - insights.citeline.com

Mar 14, 2025
pulisher
Mar 13, 2025

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Bluefield Daily Telegraph

Mar 13, 2025
pulisher
Mar 13, 2025

ChromaDex to rebrand as Niagen Bioscience and change ticker - Investing.com

Mar 13, 2025
pulisher
Mar 11, 2025

Healthy Aging Leader ChromaDex Takes Center Stage at ROTH Conference Longevity Panel - Stock Titan

Mar 11, 2025
pulisher
Mar 06, 2025

ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High - Seeking Alpha

Mar 06, 2025
pulisher
Mar 05, 2025

ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 05, 2025
pulisher
Feb 25, 2025

When Will ChromaDex Reveal Its Q4 Performance? Key Date for NAD+ Leader's Financial Results - Stock Titan

Feb 25, 2025
pulisher
Jan 06, 2025

ChromaDex to Present at Lytham Partners Healthcare Summit, Showcasing NAD+ Research Advances - StockTitan

Jan 06, 2025
pulisher
Jan 02, 2025

Daré Bioscience, Inc. and ARPA-H Ring the Nasdaq Stock Market Closing Bell - Nasdaq

Jan 02, 2025
pulisher
Nov 07, 2024

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide - Business Wire

Nov 07, 2024
pulisher
Sep 11, 2024

Thorne acquires brain health formula partner in $5 million deal - SupplySide Supplement Journal

Sep 11, 2024
pulisher
Sep 11, 2024

The proper role of pre-blends of nutrients in production of dietary supplements - SupplySide Supplement Journal

Sep 11, 2024
pulisher
Sep 10, 2024

FDA Criminal Office Said to Be Examining Drug Ostarine in Dietary Supplements - SupplySide Supplement Journal

Sep 10, 2024
pulisher
Sep 10, 2024

Technology disruption in the dietary supplement industry - SupplySide Supplement Journal

Sep 10, 2024
pulisher
Sep 10, 2024

IV and Injection Offerings to Additional Leading Wellness Clinics - Business Wire

Sep 10, 2024
pulisher
Sep 10, 2024

GMP Requirements for Softgels - SupplySide Supplement Journal

Sep 10, 2024
pulisher
Sep 09, 2024

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions - Business Wire

Sep 09, 2024
pulisher
Aug 23, 2024

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024 - Business Wire

Aug 23, 2024

Finanzdaten der Niagen Bioscience Inc-Aktie (NAGE)

Es liegen keine Finanzdaten für Niagen Bioscience Inc (NAGE) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.65
price up icon 0.63%
$70.47
price up icon 1.28%
$32.49
price up icon 0.64%
$23.90
price up icon 1.85%
$108.35
price up icon 3.89%
biotechnology ONC
$247.87
price up icon 1.21%
Kapitalisierung:     |  Volumen (24h):